Last reviewed · How we verify
Diflucan IV, oral
Diflucan (fluconazole) inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.
Diflucan (fluconazole) inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Candidiasis (oropharyngeal, esophageal, vaginal, systemic), Cryptococcal meningitis, Fungal prophylaxis in immunocompromised patients.
At a glance
| Generic name | Diflucan IV, oral |
|---|---|
| Sponsor | Pfizer |
| Drug class | Triazole antifungal |
| Target | Lanosterol 14α-demethylase (CYP51) |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
Fluconazole is a triazole antifungal that selectively targets fungal sterol synthesis by inhibiting the enzyme lanosterol 14α-demethylase (CYP51). This prevents the conversion of lanosterol to ergosterol, a critical component of the fungal cell membrane, leading to membrane instability and fungal cell death. The drug has broad-spectrum activity against many Candida species, Cryptococcus, and other fungi.
Approved indications
- Candidiasis (oropharyngeal, esophageal, vaginal, systemic)
- Cryptococcal meningitis
- Fungal prophylaxis in immunocompromised patients
- Coccidioidomycosis
Common side effects
- Headache
- Nausea
- Abdominal pain
- Diarrhea
- Rash
- Elevated liver enzymes
- QT prolongation
Key clinical trials
- A Phase 3 Efficacy and Safety Study of Fosmanogepix for the Treatment of Adult Participants With Candidemia and/or Invasive Candidiasis. (PHASE3)
- A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based Graft-Versus-Host Disease Prophylaxis in Patients With Hematologic Malignancies Undergoing Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation (PHASE2)
- A Study to Learn How Fluconazole, Carbamazepine and Itraconazole Affect How the Body Processes ASP3082 in Healthy Adults (PHASE1)
- Trial of Novel Anti-leukemia Agents in Flu/Mel RIC Transplant for Myeloid Malignancies (PHASE1)
- Study of Rezafungin Compared to Standard Antimicrobial Regimen for Prevention of Invasive Fungal Diseases in Adults Undergoing Allogeneic Blood and Marrow Transplantation (PHASE3)
- Platform Trial For Cryptococcal Meningitis (PHASE2, PHASE3)
- A Phase 3, Randomized, Double-blind Study for Patients With Invasive Candidiasis Treated With IV Echinocandin Followed by Either Oral Ibrexafungerp or Oral Fluconazole (PHASE3)
- Study of Biomarker-Based Treatment of Acute Myeloid Leukemia (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Diflucan IV, oral CI brief — competitive landscape report
- Diflucan IV, oral updates RSS · CI watch RSS
- Pfizer portfolio CI